PURPOSE: Early-stage cancers are routinely treated with surgery followed by radiotherapy (SR). Radiotherapy before surgery (RS) has been widely ignored for some cancers. We evaluate overall survival (OS) and disease-free survival (DFS) with SR and RS for different cancer types and simulate the plausibility of RS- and SR-induced antitumor immunity contributing to outcomes. MATERIALS AND METHODS: We analyzed a SEER data set of early-stage cancers treated with SR or RS. OS and DFS were calculated for cancers with sufficient numbers for statistical power (cancers of lung and bronchus, esophagus, rectum, cervix uteri, corpus uteri, and breast). We simulated the immunologic consequences of SR, RS, and radiotherapy alone in a mathematical model of tumor-immune interactions. RESULTS: RS improved OS for cancers with low 20-year survival rates (lung: hazard ratio [HR], 0.88; P = .046) and improved DFS for cancers with higher survival (breast: HR = 0.64; P < .001). For rectal cancer, with intermediate 20-year survival, RS improved both OS (HR = 0.89; P = .006) and DFS (HR = 0.86; P = .04). Model simulations suggested that RS could increase OS by eliminating cancer for a broader range of model parameters and radiotherapy-induced antitumor immunity compared with SR for selected parameter combinations. This could create an immune memory that may explain increased DFS after RS for certain cancers. CONCLUSION: Study results suggest plausibility that radiation to the bulk of the tumor could induce a more robust immune response and better harness the synergy of radiotherapy and antitumor immunity than postsurgical radiation to the tumor bed. This exploratory study provides motivation for prospective evaluation of immune activation of RS versus SR in controlled clinical studies.
PURPOSE: Early-stage cancers are routinely treated with surgery followed by radiotherapy (SR). Radiotherapy before surgery (RS) has been widely ignored for some cancers. We evaluate overall survival (OS) and disease-free survival (DFS) with SR and RS for different cancer types and simulate the plausibility of RS- and SR-induced antitumor immunity contributing to outcomes. MATERIALS AND METHODS: We analyzed a SEER data set of early-stage cancers treated with SR or RS. OS and DFS were calculated for cancers with sufficient numbers for statistical power (cancers of lung and bronchus, esophagus, rectum, cervix uteri, corpus uteri, and breast). We simulated the immunologic consequences of SR, RS, and radiotherapy alone in a mathematical model of tumor-immune interactions. RESULTS:RS improved OS for cancers with low 20-year survival rates (lung: hazard ratio [HR], 0.88; P = .046) and improved DFS for cancers with higher survival (breast: HR = 0.64; P < .001). For rectal cancer, with intermediate 20-year survival, RS improved both OS (HR = 0.89; P = .006) and DFS (HR = 0.86; P = .04). Model simulations suggested that RS could increase OS by eliminating cancer for a broader range of model parameters and radiotherapy-induced antitumor immunity compared with SR for selected parameter combinations. This could create an immune memory that may explain increased DFS after RS for certain cancers. CONCLUSION: Study results suggest plausibility that radiation to the bulk of the tumor could induce a more robust immune response and better harness the synergy of radiotherapy and antitumor immunity than postsurgical radiation to the tumor bed. This exploratory study provides motivation for prospective evaluation of immune activation of RS versus SR in controlled clinical studies.
Authors: Jan T Poleszczuk; Kimberly A Luddy; Sotiris Prokopiou; Mark Robertson-Tessi; Eduardo G Moros; Mayer Fishman; Julie Y Djeu; Steven E Finkelstein; Heiko Enderling Journal: Cancer Res Date: 2016-02-01 Impact factor: 12.701
Authors: Jan Poleszczuk; Kimberly Luddy; Lu Chen; Jae K Lee; Louis B Harrison; Brian J Czerniecki; Hatem Soliman; Heiko Enderling Journal: Breast Cancer Res Date: 2017-06-30 Impact factor: 6.466
Authors: Rachel Walker; Jan Poleszczuk; Shari Pilon-Thomas; Sungjune Kim; Alexander A R A Anderson; Brian J Czerniecki; Louis B Harrison; Eduardo G Moros; Heiko Enderling Journal: Sci Rep Date: 2018-06-21 Impact factor: 4.379
Authors: Aaron R Muncey; Sephalie Y Patel; Christopher J Whelan; Robert S Ackerman; Robert A Gatenby Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302
Authors: Juan Carlos L Alfonso; Lito A Papaxenopoulou; Pietro Mascheroni; Michael Meyer-Hermann; Haralampos Hatzikirou Journal: iScience Date: 2020-02-11
Authors: Mohammad U Zahid; Nuverah Mohsin; Abdallah S R Mohamed; Jimmy J Caudell; Louis B Harrison; Clifton D Fuller; Eduardo G Moros; Heiko Enderling Journal: Int J Radiat Oncol Biol Phys Date: 2021-06-05 Impact factor: 7.038